In vitro effects of S-Licarbazepine as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders.

Erva BayraktarYuanyuan LiuLukas SonnenbergUlrike B S HedrichYildirim SaraAhmed EltokhiHang LyuHolger LercheThomas V WuttkeStephan Lauxmann

Published in: British journal of pharmacology (2022)

S-Licarbazepine not only owns substance- but also variant-specific effects. Personalized treatment regimens optimized to achieve such variant-specific pharmacological modulation may help to reduce adverse side effects and improve the overall therapeutic outcome of SCN8A-related disease.

Keyphrases

copy number
stem cells
gene expression
human health
risk assessment
dna methylation
replacement therapy
bone marrow